Wendy Mcdermott
Human Resources Officer at LEXICON PHARMACEUTICALS, INC.
Net worth: 81 149 $ as of 2024-04-29
Wendy Mcdermott active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Human Resources Officer | 2021-12-31 | - |
Career history of Wendy Mcdermott
Former positions of Wendy Mcdermott
| Companies | Position | Start | End |
|---|---|---|---|
| Sanofi Corp. | Human Resources Officer | 2016-12-31 | 2018-12-31 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Human Resources Officer | 2018-12-31 | - |
Training of Wendy Mcdermott
| State University of New York College at Plattsburgh | Undergraduate Degree |
Statistics
International
| United States | 5 |
Operational
| Human Resources Officer | 3 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Sanofi Corp. |
- Stock Market
- Insiders
- Wendy Mcdermott
- Experience